There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were ...

INVESTIGATORS AND CLINICIANS anticipate that the next wave of therapeutic approaches in renal cell carcinoma (RCC) will target hypoxia-inducible factor-2 (HIF-2), a transcription factor that is ...

Localised renal cell carcinoma (RCC) is usually treated surgically, with post-operative imaging-based surveillance to monitor for recurrence. However, surveillance practices vary widely, and patients ...

High nuclear accumulation of NONO-TFE3 or PRCC-TFE3 fusion proteins promotes their broad binding across the genome at H3K27ac-marked active chromatin, engaging a core set of M/E-box-containing ...

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license Self-reported Black (B) individuals remain underrepresented in molecular studies of ...